Publicacións en colaboración con investigadores/as de Centro de Investigación en Red en Enfermedades Cardiovasculares (65)

2022

  1. Challenges in managing patients with heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 1-7

  2. Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy

    Cells, Vol. 11, Núm. 2

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  4. Minimal invasive fluorescence methods to quantify advanced glycation end products (AGEs) in skin and plasma of humans

    Methods, Vol. 203, pp. 103-107

  5. Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14

  6. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

  7. Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29

  8. Vericiguat: VICTORIA trial results

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 15-22

2021

  1. Biocompatibility analysis of thermal and UV-curable polydimethylsiloxane for semi blood vessel-like model fabrication

    Optics InfoBase Conference Papers

  2. Biocompatibility analysis of thermal and UV-curable polydimethylsiloxane for semi blood vessel-like model fabrication

    2021 Conference on Lasers and Electro-Optics Europe and European Quantum Electronics Conference, CLEO/Europe-EQEC 2021

  3. Constrictive pericarditis

    Medicine (Spain), Vol. 13, Núm. 43, pp. 2517-2531

  4. Correction to: Galectin-3 and soluble RAGE as new biomarkers of post-infarction cardiac remodeling (Journal of Molecular Medicine, (2021), 99, 7, (943-953), 10.1007/s00109-021-02054-6)

    Journal of Molecular Medicine

  5. Debate: Refractory angina. The Reducer device as a new therapeutic approach. Perspective from the clinic

    REC: Interventional Cardiology

  6. Diagnostic protocol for constrictive pericarditis

    Medicine (Spain), Vol. 13, Núm. 43, pp. 2543-2547

  7. Diagnostic protocol for patients with pericarditis and fever

    Medicine (Spain), Vol. 13, Núm. 43, pp. 2548-2551

  8. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169

  9. Galectin-3 and soluble RAGE as new biomarkers of post-infarction cardiac remodeling

    Journal of Molecular Medicine, Vol. 99, Núm. 7, pp. 943-953

  10. Haemodynamic-dependent arrest of circulating tumour cells at large blood vessel bifurcations as new model for metastasis

    Scientific Reports, Vol. 11, Núm. 1

  11. Higher ACE2 expression levels in epicardial cells than subcutaneous stromal cells from patients with cardiovascular disease: Diabetes and obesity as possible enhancer

    European Journal of Clinical Investigation, Vol. 51, Núm. 5

  12. Impact of statins in patients with COVID-19

    Revista Espanola de Cardiologia, Vol. 74, Núm. 7, pp. 637-640